TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation

Oncogene

Volumn 34, Issue 29, 2015, Pages 3815-3825

  Mounir, Z ^a   Lin, F ^a   Lin, V G ^a   Korn, J M ^a   Yu, Y ^a   Valdez, R ^a   Aina, O H ^b   Buchwalter, G ^c,d   Jaffe, A B ^a   Korpal, M ^a,e   Zhu, P ^a,e   Brown, M ^c,d   Cardiff, R D ^b   Rocnik, J L ^a,f   Yang, Y ^a   Pagliarini, R ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e EISAI INC   (United States)

^f SANOFI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTINEOPLASTIC ANTIBIOTIC; DOXORUBICIN; ENZALUTAMIDE; ERG PROTEIN, HUMAN; ONCOPROTEIN; PHENYLTHIOHYDANTOIN; SERINE PROTEINASE; TMPRSS2 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL POPULATION; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CELL SELECTION; CONTROLLED STUDY; ERG GENE; FUSION GENE; GENE EXPRESSION; GENE FUSION; GENETIC TRANSCRIPTION; HORMONAL REGULATION; HUMAN; HUMAN CELL; LUMINAL CELL; MOUSE; NERVE CELL DIFFERENTIATION; NEUROSECRETORY CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION; TRANSMEMBRANE PROTEASE SERINE 2 GENE; ANALOGS AND DERIVATIVES; ANIMAL; CELL DIFFERENTIATION; CONFOCAL MICROSCOPY; DISEASE MODEL; DRUG EFFECTS; EPITHELIUM CELL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE TRANSLOCATION; GENETICS; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSGENIC MOUSE; TUMOR CELL LINE;

MUS MUSCULUS;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DOXORUBICIN; EPITHELIAL CELLS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE, TRANSGENIC; MICROSCOPY, CONFOCAL; NEUROENDOCRINE CELLS; ONCOGENE PROTEINS, FUSION; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SERINE ENDOPEPTIDASES; TRANS-ACTIVATORS; TRANSLOCATION, GENETIC;

EID: 84937500858     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.308     Document Type: Article

References (46)

1. Clark JP, Cooper CS. ETS gene fusions in prostate cancer. Nat Rev Urol 2009; 6: 429-439.
2. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-648.
3. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008; 10: 177-188.
4. Gupta S, Iljin K, Sara H, Mpindi JP, Mirtti T, Vainio P et al. FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res 2010; 70: 6735-6745.
5. Baena E, Shao Z, Linn DE, Glass K, Hamblen MJ, Fujiwara Y et al. ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients. Genes Dev 2013; 27: 683-698.
6. King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, Leung DH et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 2009; 41: 524-526.
7. Mani RS, Iyer MK, Cao Q, Brenner JC, Wang L, Ghosh A et al. TMPRSS2-ERGmediated feed-forward regulation of wild-type ERG in human prostate cancers. Cancer Res 2011; 71: 5387-5392.
8. Casey OM, Fang L, Hynes PG, Abou-Kheir WG, Martin PL, Tillman HS et al. TMP. PLoS ONE 2012; 7: e41668.
9. Chen Y, Chi P, Rockowitz S, Iaquinta PJ, Shamu T, Shukla S et al. ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nat Med 2013; 19: 1023-1029.
10. Klezovitch O, Risk M, Coleman I, Lucas JM, Null M, True LD et al. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci USA 2008; 105: 2105-2110.
11. Aumuller G, Leonhardt M, Janssen M, Konrad L, Bjartell A, Abrahamsson PA. Neurogenic origin of human prostate endocrine cells. Urology 1999; 53: 1041-1048.
12. Yu J, Yu J, Mani RS, Cao Q, Brenner CJ, Cao X et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 2010; 17: 443-454.
13. Simon RA, di Sant'Agnese PA, Huang LS, Xu H, Yao JL, Yang Q et al. CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers. Hum Pathol 2009; 40: 252-258.
14. Palapattu GS, Wu C, Silvers CR, Martin HB, Williams K, Salamone L et al. Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer. Prostate 2009; 69: 787-798.
15. Signoretti S, Pires MM, Lindauer M, Horner JW, Grisanzio C, Dhar S et al. p63 regulates commitment to the prostate cell lineage. Proc Natl Acad Sci USA 2005; 102: 11355-11360.
16. Yuan TC, Veeramani S, Lin FF, Kondrikou D, Zelivianski S, Igawa T et al. Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells. Endocr Relat Cancer 2006; 13: 151-167.
17. Wang J, Cai Y, Yu W, Ren C, Spencer DM, Ittmann M. Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Res 2008; 68: 8516-8524.
18. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324: 787-790.
19. Mertz KD, Setlur SR, Dhanasekaran SM, Demichelis F, Perner S, Tomlins S et al. Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. Neoplasia 2007; 9: 200-206.
20. Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, Perner S et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst 2008; 100: 815-825.
21. Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 2009; 41: 619-624.
22. Sun C, Dobi A, Mohamed A, Li H, Thangapazham RL, Furusato B et al. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 2008; 27: 5348-5353.
23. Carmichael CL, Metcalf D, Henley KJ, Kruse EA, Di RL, Mifsud S et al. Hematopoietic overexpression of the transcription factor Erg induces lymphoid and erythro-megakaryocytic leukemia. Proc Natl Acad Sci USA 2012; 109: 15437-15442.
24. Bostwick DG, Dousa MK, Crawford BG, Wollan PC. Neuroendocrine differentiation in prostatic intraepithelial neoplasia and adenocarcinoma. Am J Surg Pathol 1994; 18: 1240-1246.
25. Li Z, Chen CJ, Wang JK, Hsia E, Li W, Squires J et al. Neuroendocrine differentiation of prostate cancer. Asian J Androl 2013; 15: 328-332.
26. Jongsma J, Oomen MH, Noordzij MA, Romijn JC, van der Kwast TH, Schroder FH et al. Androgen-independent growth is induced by neuropeptides in human prostate cancer cell lines. Prostate 2000; 42: 34-44.
27. Sehgal I, Powers S, Huntley B, Powis G, Pittelkow M, Maihle NJ. Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer. Proc Natl Acad Sci USA 1994; 91: 4673-4677.
28. Papandreou CN, Usmani B, Geng Y, Bogenrieder T, Freeman R, Wilk S et al. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med 1998; 4: 50-57.
29. Burchardt T, Burchardt M, Chen MW, Cao Y, de la Taille A, Shabsigh A et al. Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo. J Urol 1999; 162: 1800-1805.
30. Jin RJ, Wang Y, Masumori N, Ishii K, Tsukamoto T, Shappell SB et al. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Cancer Res 2004; 64: 5489-5495.
31. Matei DV, Renne G, Pimentel M, Sandri MT, Zorzino L, Botteri E et al. Neuroendocrine differentiation in castration-resistant prostate cancer: a systematic diagnostic attempt. Clin Genitourin Cancer 2012; 10: 164-173.
32. Svensson C, Ceder J, Iglesias-Gato D, Chuan YC, Pang ST, Bjartell A et al. REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer. Nucleic Acids Res 2014; 42: 999-1015.
33. Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 2011; 1: 487-495.
34. Lotan TL, Gupta NS, Wang W, Toubaji A, Haffner MC, Chaux A et al. ERG gene rearrangements are common in prostatic small cell carcinomas. Mod Pathol 2011; 24: 820-828.
35. Schelling LA, Williamson SR, Zhang S, Yao JL, Wang M, Huang J et al. Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry. Hum Pathol 2013; 44: 2227-2233.
36. Yuan TC, Veeramani S, Lin MF. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr Relat Cancer 2007; 14: 531-547.
37. Cher ML, Bova GS, Moore DH, Small EJ, Carroll PR, Pin SS et al. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res 1996; 56: 3091-3102.
38. Balbas MD, Evans MJ, Hosfield DJ, Wongvipat J, Arora VK, Watson PA et al. Overcoming mutation-based resistance to antiandrogens with rational drug design. Elife 2013; 2: e00499.
39. Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 2013; 155: 1309-1322.
40. Korpal M, Korn JM, Gao X, Rakiec DP, Ruddy DA, Doshi S et al. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov 2013; 3: 1030-1043.
41. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995; 9: 401-406.
42. Yang JC, Ok JH, Busby JE, Borowsky AD, Kung HJ, Evans CP. Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgeninsensitive prostate cancer. Cancer Res 2009; 69: 151-160.
43. Lee LF, Guan J, Qiu Y, Kung HJ. Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase. Mol Cell Biol 2001; 21: 8385-8397.
44. Sun H, Qin B, Liu T, Wang Q, Liu J, Wang J et al. Cistrome Finder for ChIP-seq and DNase-seq data reuse. Bioinformatics 2013; 29: 1352-1354.
45. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM et al. The human genome browser at UCSC. Genome Res 2002; 12: 996-1006.
46. Meyer LR, Zweig AS, Hinrichs AS, Karolchik D, Kuhn RM, Wong M et al. The UCSC Genome Browser database: extensions and updates 2013. Nucleic Acids Res 2013 41: D64-D69.